Caption Management’s Heron Therapeutics HRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-339,100
Closed -$441K 1761
2025
Q4
$441K Buy
+339,100
New +$419K ﹤0.01% 1262
2025
Q3
Sell
-1,505,900
Closed -$3.12M 1829
2025
Q2
$3.12M Buy
+1,505,900
New +$3.08M 0.03% 566
2022
Q2
Sell
-133,300
Closed -$763K 1612
2022
Q1
$763K Sell
133,300
-7,900
-6% -$57.8K 0.01% 1043
2021
Q4
$1.29M Buy
+141,200
New +$1.44M 0.01% 953
2021
Q2
Sell
-88,600
Closed -$1.44M 1415
2021
Q1
$1.44M Buy
+88,600
New +$1.58M 0.03% 597
2020
Q2
Sell
-60,000
Closed -$703K 1048
2020
Q1
$703K Buy
+60,000
New +$1.13M 0.04% 484

Other funds holding HRTX

Caption Management's HRTX Position: Q1 2026 in Review

Caption Management opened a new position in Heron Therapeutics (HRTX) in Q1 2026: 313,681 shares worth $251K. The stake represents ﹤0.01% of the portfolio and ranks #1316 among its holdings. This is a return to the name: Caption Management previously reported a position in HRTX as recently as Q3 2025.

Caption Management first reported a position in HRTX in Q1 2019 and has held it in 9 quarters since. The position peaked at $3.19M in Q4 2021. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Caption Management held 313,681 shares of Heron Therapeutics worth $251K as of Q1 2026.
  • Heron Therapeutics was a new Caption Management position in Q1 2026.
  • Heron Therapeutics made up ﹤0.01% of Caption Management's portfolio in Q1 2026, its #1316 holding.
  • Caption Management first reported a position in Heron Therapeutics in Q1 2019 and has held it in 9 quarters since.
  • Caption Management's Heron Therapeutics position peaked at $3.19M in Q4 2021.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.